Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea, Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics...

In January of this year, in a major regulatory milestone, New York State Department of Health approved a new AI-based digital pathology diagnostic test for breast cancer. The test, developed by PreciseDx, is performed on tumor samples removed...

Kristalyn Gallagher, DO, Kevin Chen, MD, and Shawn Gomez, EngScD, in the UNC School of Medicine have developed an AI model that can predict whether or not cancerous tissue has been fully removed from the body during breast cancer...

Gestalt Diagnostics: Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models SPOKANE, Wash., Sept. 19, 2023 /PRNewswire/ -- Gestalt Diagnostics is proud to announce our latest release – an AI algorithm for use on one of...

Ibex: Developed in Collaboration with AstraZeneca and Daiichi Sankyo, Galen™ Breast HER2 Aids Pathologists with Reproducible HER2 Assessment  TEL AVIV, Israel, Sept. 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in...

HER2 IHC testing in the wake of the 2023 HER2 Breast Guideline Update Clinical Value, Classification & Scoring and the impact of the ASCO-CAP 2023 HER2 Breast Testing Guideline Update Over the past several months, the HER2/neu IHC...